Back to Search

A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor Everolimus in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer


  • Protocol Number: 202212077
  • Principal Investigator: Ma, Cynthia
  • Cancer Types: Breast

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions